Abstract. Radiotherapy is one of the primary methods of treatment of malignant tumors, however, resistance to radiation is a major problem. The reasons for the radioresistance are still poorly understood. However, it is generally accepted that microRNAs (miRNAs or miRs) can regulate the radiosensitivity of tumors. The present study therefore aimed to identify specific miRNAs and their effects on radioresistant cells. More specifically, the aim was to investigate specific miRNAs and their effects on radioresistant tumor cells. The radioresistant tumor cells (CNE-2R) were established using a dose gradient method, and the miRNA expression profiles of CNE-2R cells and the parental cells (CNE-2) were determined. The expression of miR-210 in CNE-2R cells was significantly higher than in CNE-2 cells. CNE-2R cells were transfected with LV-hsa-miR-210-inhibitor, and CNE-2 cells were transfected with LV-hsa-miR-210. The expression of miR-210 was confirmed by reverse transcription quantitative-polymerase chain reaction. The percentages of CNE-2R-miR-210-inhibitor and CNE-2 cells in the G 2 /M phase were higher than in the CNE-2R and CNE-2-miR-210 cells, and the percentages of cells in S phase were lower than in the CNE-2R and CNE-2-miR-210 cells. Following 4 Gy of radiation, CNE-2R-miR-210-inhibitor and CNE-2 cells, which express low levels of miR-210, had a higher apoptosis rate than CNE-2R and CNE-2-miR-210 cells. Following 4, 8 and 12 Gy of radiation, cell viability and survival fraction of CNE-2R-miR-210-inhibitor cells were lower than those of CNE-2R and CNE-2-miR-210 cells, and similar to those of CNE-2 cells. Together, these findings strongly suggest that miR-210 negatively regulates the radiosensitivity of tumor cells, and may therefore have therapeutic potential for the treatment of radiation resistance.
Introduction
Presently, the primary treatments of cancer include surgery, radiotherapy, chemotherapy and targeted therapy. Radiotherapy is the main treatment used for cancer (1) . It is widely used for the treatment of tumors in rectal cancer, non-small cell lung cancer and breast cancer (2) (3) (4) .
For example, radiotherapy is the preferred and primary treatment for nasopharyngeal cancer (NPC) (5) . Following radiotherapy, the five-year survival percentage for patients with NPC has increased from 50-60% to a current percentage of ~70%. However, following radical radiotherapy, ~20% of NPC patients still have residual tumors (6) . Local treatment failure and distant metastasis are the key factors which prevent therapeutic efficacy, and intrinsic or acquired radiation resistance is one of the primary reasons causing the failure of radiotherapy and worse treatment outcomes (7, 8) .
Thus, it is important to gain further insights into the molecular mechanisms of chemotherapeutic drug resistance, and find novel strategies involving improved therapeutic benefits for cancer patients. microRNAs (miRNAs) are a class of small RNAs with an approximate length of 19-25 nucleotides, which are endogenous short noncoding RNAs (9) . miRNAs bind to the 3'-untranslated region of target mRNAs, followed by degradation of the mRNA or inhibition of its translation. They may also regulate the expression of target genes at the post-transcriptional level (10) , and are associated with regulating cell growth, proliferation, differentiation and apoptosis (11) . miRNAs are observed in many cancers, and are involved in malignant tumor development and progression (12) . Several studies have reported that the expressions of miRNAs are closely associated with the radiosensitivity of tumors, and upregulated or downregulated expression of miRNAs can increase tumor radiosensitivity (13) . To address these possibilities, the following study characterized the effects of miRNAs on the radiation resistance of tumor cells, in order to provide a biochemical basis for further studies, which may use this biomarker to predict the radiosensitivity of cancer patients.
Materials and methods
Cells and cell culture. The CNE-2 cell line, which is suspected to be identical to CNE-1 and cross-contaminated with HeLa Development of acquired radioresistant cells. CNE-2 cells were cultured in 25 cm 2 culture flasks. The cells were exposed to a series of increasing X-ray doses using a medical electronic linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), in order to establish the radiation resistant tumor cells (CNE-2R). The distance of the source was 100 cm, and the radiation field was 10x10 cm at a dose rate of 300 cGy/min. Cells were irradiated twice with 2 Gy, four times with 4 Gy, and five times with 6 Gy with X-ray radiation over a period of 6 months, so that the CNE-2 cells were exposed to a total dose of 50 Gy. Following several cell passages, the radiation resistant tumor cells were established.
Apoptosis assay. The cells were radiated with 0 and 4 Gy of radiation. Following 12 h, many cells were detached with trypsin without the use of EDTA. Cells were harvested in culture medium and centrifuged for 5 min at 300 x g, and 1x10
5 cells were treated with 5 µl Annexin V/PE and 10 µl 7-AAD (BD Biosciences, Franklin Lakes, NJ, USA). The cells were gently vortexed and incubated for 15 min at room temperature in the dark. A total of 400 µl 1X binding buffer was added into solution, the cells were analyzed using a Gallios flow cytometer (Beckman Coulter, Inc., Brea, CA, USA).
Cell cycle assay. The cells were digested with trypsin, and were centrifuged for 5 min at 300 x g. Then the cells were resuspended twice with 2 ml PBS, fixed with 1 ml 70% ice cold ethanol, and stored at 4˚C overnight. Then 100 µg/ml RNase and 50 µg/ml PI were added, and following incubation in the dark for 30 min, the cell cycle was detected using a Gallios flow cytometer.
Cell viability assay. The cells (5x10 3 ) were seeded into 96-well plates. After the cells adhered to the plate, they were irradiated with different doses of X-ray radiation using 0, 4, 8 and 12 Gy, followed by incubation for 24 h. Medium (100 µl) was mixed with 10 µl of CCK-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), and a total of 110 µl of the mixed solution was added to each well, followed by incubation of the cells for 2 h. The absorbance at 450 nm of the cells was then read using a microplate reader (Tecan Group Ltd., Männedorf, Switzerland).
Colony formation assay. The surviving cells were characterized using a colony formation assay. Two hundred cells were seeded into six-well plates. After the cells adhered, they were exposed to X-ray radiation with single doses of 0, 4, 8 and 12 Gy, and the cells were incubated for 2 weeks without disturbance. After 2 weeks, there were >50 cells in each colony. The cells were fixed with 4% paraformaldehyde for 30 min and stained with crystal violet solution for 30 min, and the colonies counted. The percentage of cell survival was calculated as follows: The numbers of colonies at x Gy/(the numbers of cells seeded at a x Gy colony forming rate).
MicroRNA microarray analysis. CapitalBio Technology Co., Ltd. (Beijing, China) conducted the present study's Agilent Human miRNA microarrays, which were 8x60 K microarrays used for detecting miRNA expression profiles of the CNE-2 and CNE-2R cells. There were many differential expressions of miRNAs using the microRNA microarray. Among these differential expressions, miR-210 had a significant fold change and a high probe signal, so miR-210 was chosen for further assays. Differences of miR-210 in the CNE-2 and CNE-2R cells were measured by RT-qPCR.
Overexpression of miR-210 in CNE-2 cells and downregulation of miR-210 in CNE-2R cells. CNE-2R cells were transfected
with LV-hsa-miR-210-inhibitor, which is a lentivirus inhibiting miR-210 loaded with green fluorescent protein (GFP; GeneChem Co., Ltd., Shanghai, China), and CNE-2 cells were transfected with LV-hsa-miR-210 + GFP, which is a lentivirus expressing miR-210 (GeneChem Co., Ltd.). Following infection with the virus, the infected cells were screened by puromycin for 1 month to establish stable downregulated and upregulated cells. Overexpression of miR-210 in CNE-2 cells resulted in CNE-2-miR-210 cells, and downregulation of miR-210 in CNE-2R cells resulting in CNE-2R-miR-210-inhibitor cells.
RT-qPCR.
Total cellular RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), then the RNA samples were used for cDNA synthesis using an All-in-One ™ miRNA First-Strand cDNA Synthesis kit (GeneCopoeia, Inc., Rockville, MD, USA). miR-210 was detected with RT-qPCR by the All-in-One ™ miRNA RT-qPCR kit (GeneCopoeia, Inc.). U6 was used as the control for detection of miR-210. The miR-210 RT-qPCR primer was purchased from GeneCopoeia, Inc. All steps followed the manufacturer's protocols. The results were calculated using the 2 -ΔΔCq method (15) .
Statistical analysis. SPSS software (version, 19.0; IBM SPSS, Armonk, NY, USA) was used for all the statistical analyses.
One-way analysis of variance with Student-Newman-Keuls post hoc tests for multiple comparisons or a Student's t-test were used for the appropriate types of data. P<0.05 was considered to indicate a statistically significant difference.
Results

Radiosensitivity of the CNE-2R cells.
To verify whether the radioresistant tumor cells were established, the radiosensitivity of the CNE-2R cells was compared with the parental cells. The percentage of CNE-2 cells in G 2 /M phase was significantly greater than CNE-2R cells ( Fig. 1A ; P<0.05). At the same time, determination of cell viabilities indicated that the CNE-2R cells had lower decreases in viability than the CNE-2 cells when irradiated with 4, 8 and 12 Gy of radiation ( Fig. 1B; P<0 .05). Furthermore, the radiosensitivities of the CNE-2 and CNE-2R cells were compared using the colony formation assay, which reported that the CNE-2R cells had a greater percentage of radioresistant cells than the CNE-2 cells (Fig. 1C) . These results demonstrated that the CNE-2R cells were more radioresistant than the CNE-2 cells, and that radioresistant tumor cells were established using the stated protocol.
Expression of miRNAs and RT-qPCR verification between the CNE-2 cells and CNE-2R cells.
Microarray analyses were used to compare the patterns of miRNA expression between the acquired radioresistant CNE-2R cells and their parental CNE-2 cells. There were 92 miRNAs with expression changes greater than 2-fold in CNE-2R cells, involving 60 miRNAs that were upregulated and 32 miRNAs that were downregulated (Table I ). The expression of miR-210 in CNE-2R cells was 247.25-fold higher than the expression in CNE-2 cells (P=0.0006).
Downregulation of miR-210 in CNE-2R cells and overexpression of miR-210 in CNE-2 cells.
In order to determine the relationship between miR-210 and radioresistance, the authors transfected LV-hsa-miR-210 into CNE-2 cells ( Fig. 2A) , and transfected the LV-hsa-miR-210-inhibitor into CNE-2R cells ( (Fig. 4B, P<0 .05). The authors exposed cells to 0 or 4 Gy of X-ray radiation, and apoptosis was measured by flow cytometry. The results of flow cytometry indicated that the apoptosis percentage of CNE-2-miR-210 cells was significantly lower than CNE-2 cells ( Fig. 5A ; P<0.05), and the apoptosis percentage of CNE-2R-miR-210-inhibitor cells was significantly greater than CNE-2R cells ( Fig. 5B ; P<0.05), following irradiation by 4 Gy. However, there were no significant differences in the percentages of apoptosis of these cells in the absence of irradiation ( Fig. 5A and B) .
miR-210 negatively regulates cell viability following irradiation.
To determine whether miR-210 negatively regulates cell viability, a cell viability assay was used to determine the effect of miR-210 on cell viability with different doses of X-ray radiation of 0, 4, 8 and 12 Gy. The cell viability of CNE-2 cells was lower than CNE-2-miR-210 cells when they were radiated with 4, 8 and 12 Gy ( Fig. 6A ; P<0.05). The cell viability of CNE-2R cells was higher than CNE-2R-miR-210-inhibitor cells following being irradiated by 4, 8 and 12 Gy ( Fig. 6B ; P<0.05), demonstrating that suppression of miR-210 expression increased the viability of tumor cells.
miR-210 promotes the radioresistance of tumor cells.
In order to identify and confirm that miR-210 promotes radioresistance of tumor cells, the authors irradiated CNE-2, CNE-2R, CNE-2-miR-210 and CNE-2R-miR-210-inhibitor cells with different doses of X-ray radiation of 0, 4, 8 and 12 Gy, and determined the cell survival using a colony formation assay (Fig. 7) . As expected, the CNE-2 cells were more radiosensitive than CNE-2-miR-210 cells following X-ray treatment, and CNE-2R cells were more radioresistant than the CNE-2R-miR-210-inhibitor cells, confirming that miR-210 can promote radioresistance of tumor cells.
Target gene analysis.
It was predicted that miRNAs exerted their functions via regulating the expression of the target genes miRbase (http://mirbase.org/index.shtml), miRecords (http://mirecords.biolead.org), Tarbase (http://microrna. gr/tarbase) and TargetScan (http://www.targetscan.org). There were many potential target genes, such as HIF-1α, CTR1A, ADAMTS5 and CAMTA1. In future studies, the authors will use the luciferase reporter to identify target genes, and western blot analyses to detect differences in the translation products of these target genes. Furthermore, it is planned to characterize the mechanism of target gene radiosensitivity.
Discussion
Radiotherapy has emerged as the most important treatment for tumor, because it inhibits tumor growth and prolongs patient survival (16, 17) . Radiotherapy, which primarily involves the induction of DNA damage, is the most common therapeutic method for many types of cancers (18) . Numerous studies have reported that miRNAs are involved in the control of DNA damage or its repair mechanisms (19, 20) . In addition, miRNAs are involved in various malignant cell behaviors, including radioresistance (21) (22) (23) (24) . miR-205, miR-7, miR-100 and miR-101 have been reported to be associated with tumor radioresistance (25) (26) (27) (28) . For example, miR-218 is often absent in cervical cancer, which sensitizes human cervical cancer cells to radiotherapy by promoting apoptosis (29) . miR-148b increases the radiosensitivity of non-Hodgkin lymphoma (NHL) cells via enhancing radiation-induced apoptosis, which reported that miR-148b serves a significant role in the response of NHL to radiation (30) . miR-504 is downregulated following radiotherapy of NPC, which can be regarded as a new radioof NPC, which can be regarded as a new radio-, which can be regarded as a new radioresistant biomarker to monitor the tumor response to radiation treatment (31) . Taken together, these studies have indicated that miRNAs are crucial in mediating the radioresistance to cancer. However, there have been few reports of the possible role of miR-210 in radiation resistant tumor cells. Therefore, the objective of the present study was to investigate the possible correlation between miR-210 and the radiosensitivity of tumor cells.
The results demonstrated that miR-210 induced cell cycle arrest, and cells that had high expressions of miR-210 in the S phase were significantly decreased while the percentage of cells in G 2 /M phase increased. There are significant differences in the radiosensitivity of cells in the cell cycle. The radiosensitivity of the G 2 /M phase is high, and the S phase is the most radioresistant (32) . In addition, increased expression of miR-210 suppressed cell apoptosis. Similar to the trends observed for cell viability, the higher the expression level of miR-210, the higher the cell viability after irradiation. The colony formation assay confirmed that tumor cells with high levels of miR-210 were less sensitive to radiation. Based on these results, the expression of miR-210 is inversely correlated with the radiosensitivity of tumor cells.
However, the radiation resistance mechanism of miR-210 remains unclear (33) . It has been reported that vascular endothelial growth factor (VEGF) is one of the targets of miRNA-210 (34) . VEGF can contribute to tumorigenesis, by promoting angiogenesis and enhancing the blood supply (35) . Moreover, miR-210 has been reported to be the most highly induced miRNA in hypoxic cells (36) , and hypoxia reduces the radiosensitivity of tumor cells both in vitro and in vivo (37) . Previous studies have reported that some miRNAs can regulate the DNA damage response to radiation and participate in DNA repair pathways (38, 39) , but the mechanisms involved in radioresistance, angiogenesis, apoptosis, cell cycle control and DNA damage/repair are still unknown. Further studies are needed to identify the binding sites of miR-210 and characterize signaling pathways of miR-210.
Taken together, the presented findings provide insight into improving tumor radiosensitivity, and strongly suggest that miR-210 expression is negatively associated with the radiosensitivity of tumor cells. In addition, the results demonstrated that miR-210 may be used to predict the therapeutic effects of radiotherapy in cancer patients, suggesting that miR-210 could be a prognostic biomarker for cancer patients with radiotherapy, and may provide novel insights into the identification of therapeutic targets.
